CAL
DNA icon

Capital Analysts LLC’s Ginkgo Bioworks DNA Stock Holding History

Capital Analysts LLC’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6K Sell
918
-216
-19% -$1.8K ﹤0.01% 1332
2025
Q4 		$9K Hold
1,134
– – ﹤0.01% 1257
2025
Q3 		$17K Hold
1,134
– – ﹤0.01% 1102
2025
Q2 		$13K Hold
1,134
– – ﹤0.01% 1093
2025
Q1 		$6K Buy
+1,134
New +$11.6K ﹤0.01% 1192

Other funds holding DNA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JMFC
J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Analysts LLC's DNA Position: Q1 2026 in Review

Capital Analysts LLC reduced its Ginkgo Bioworks (DNA) stake by 19% in Q1 2026, selling an estimated $1.8K and leaving 918 shares worth $6K. The position accounts for ﹤0.01% of the portfolio, ranked #1332.

Capital Analysts LLC first reported a position in DNA in Q1 2025 and has held it in 5 quarters since. The position peaked at $17K in Q3 2025. 174 funds tracked by Wall St. Rank hold DNA as of Q1 2026.

  • Capital Analysts LLC held 918 shares of Ginkgo Bioworks worth $6K as of Q1 2026.
  • Capital Analysts LLC sold 216 Ginkgo Bioworks shares in Q1 2026, an estimated $1.8K.
  • Ginkgo Bioworks made up ﹤0.01% of Capital Analysts LLC's portfolio in Q1 2026, its #1332 holding.
  • Capital Analysts LLC first reported a position in Ginkgo Bioworks in Q1 2025 and has held it in 5 quarters since.
  • Capital Analysts LLC's Ginkgo Bioworks position peaked at $17K in Q3 2025.
  • 174 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q1 2026.

Based on Capital Analysts LLC's 13F filing for Q1 2026, filed 14 May 2026.